EU/3/06/365

Table of contents

About

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in November 2017, at the end of the 10-year period of market exclusivity.

On 6 April 2006, orphan designation (EU/3/06/365) was granted by the European Commission to Wyeth Europa Limited, United Kingdom, for temsirolimus for the treatment of renal cell carcinoma.

The sponsorship was transferred to Pfizer Limited, United Kingdom, in September 2011.

Temsirolimus in treatment of renal cell carcinoma has been authorised in the EU as Torisel 19 November 2007.

Key facts

Active substance
Temsirolimus
Medicine name
Torisel
Disease / condition
Treatment of renal cell carcinoma
Date of first decision
06/04/2006
Outcome
Expired
EU designation number
EU/3/06/365

Sponsor's contact details

Pfizer Limited
Ramsgate Road
Sandwich
Kent CT13 9NJ
United Kingdom
Te. +44 (0)1304 616161
Fax: +44 (0)1304 652144
E-mail: orphan_enquiries@pfizer.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating